ABSTRACT
The importance of glycemic control in preventing the chronic and devastating complications of diabetes is well established. Insulin administration is an important therapeutic option for managing diabetes, particularly for patients with profound insulin deficiency. Many insulin formulations are on the market, including short-acting insulin analogues, inhaled insulin, concentrated insulin, and basal insulin. Each category has a unique onset, peak, and duration of action. This article reviews the differing pharmacokinetic and pharmacodynamic properties and safety and efficacy data, and discusses the implications for clinical practice.
- Copyright © 2016 The Cleveland Clinic Foundation. All Rights Reserved.
- Luigi Meneghini, MD, MBA⇑
- Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center and Parkland Health & Hospital System, Dallas, TX
- Correspondence:
Luigi Meneghini, MD, MBA, Professor of Internal Medicine, University of Texas Southwestern Medical Center, Division of Endocrinology, 5323 Harry Hines Blvd., Dallas, TX 75390; Luigi.Meneghini{at}UTSouthwestern.edu
ABSTRACT
The importance of glycemic control in preventing the chronic and devastating complications of diabetes is well established. Insulin administration is an important therapeutic option for managing diabetes, particularly for patients with profound insulin deficiency. Many insulin formulations are on the market, including short-acting insulin analogues, inhaled insulin, concentrated insulin, and basal insulin. Each category has a unique onset, peak, and duration of action. This article reviews the differing pharmacokinetic and pharmacodynamic properties and safety and efficacy data, and discusses the implications for clinical practice.
- Copyright © 2016 The Cleveland Clinic Foundation. All Rights Reserved.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.